Oncolytics Biotech
Develops pelareorep, a double-stranded RNA immunotherapy for gastrointestinal tumors.
Something off on this page? Send us feedback.
Profile
Develops pelareorep, a double-stranded RNA immunotherapy being advanced as a platform for gastrointestinal tumors. It is a clinical-stage business centered on a single lead candidate, with no approved commercial product described in the reviewed materials.
Develops pelareorep, a double-stranded RNA immunotherapeutic agent that traces back to the REOLYSIN program. The development-stage business is centered on that single candidate, which is being advanced as a platform immunotherapy for gastrointestinal tumors.
Pancreatic and colorectal programs have FDA Fast Track designations. The reviewed materials do not describe an approved commercial product, and the company keeps its headquarters in San Diego while retaining a Calgary office.
Clinical development and regulatory milestones are the central operating activities. Continued operations depend on additional financing; existing cash was reported as sufficient for near-term milestones but not for a full year of planned operations from the filing date.
Company facts
Key statistics
Year to date −12.3% · Average volume (30d) 834.9K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026Q2 FY26 | −$0.05 | −$0.08 | −48.7% | — | — | — | +0.45% |
| May 14, 2026Q1 FY26 | −$0.05 | −$0.08 | −60.0% | — | — | — | −2.62% |
| Mar 30, 2026Q4 FY25 | −$0.06 | −$0.08 | −33.3% | — | — | — | +5.44% |
| Nov 12, 2025Q3 FY25 | −$0.12 | −$0.10 | +16.7% | — | — | — | −5.26% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | |
| Operating income | −$5.0M | −$4.2M | −$9.9M | −$9.7M | −$9.3M | −$9.4M | |
| Net income | −$4.7M | −$4.5M | −$10.3M | −$9.2M | −$9.2M | −$9.4M | |
| Diluted EPS | −$0.08 | −$0.07 | −$0.14 | −$0.01 | −$0.11 | −$0.08 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $4.1M · Total debt $448.0K · Total assets $7.7M · Shareholders' equity −$6.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 100.36M · Float —
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Anson Funds Management LP | 7.65M | 7.00% | 13G | Nov 14, 2025 |
| Marshall Wace, LLP | 745.4K | 0.74% | 13F | Aug 13, 2026 |
| Bernd R. Seizinger · director | 567.0K | 0.56% | Form 4 | Feb 13, 2026 |
| Wayne Pisano · director | 492.4K | 0.49% | Form 4 | Feb 13, 2026 |
| Kirk Look · officer: Chief Financial Officer | 287.5K | 0.29% | Form 4 | Feb 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 12, 2026 | Jared Kelly | director, officer: Chief Executive Officer | +5,050 | $0.9600 |
| Mar 11, 2026 | James T. Parsons | director | +10,000 | $1.03 |
| Feb 12, 2026 | Patricia S. Andrews | director | +35,400 | $0.8557 |
| Feb 11, 2026 | Andrew Aromando | officer: Chief Business Officer | +29,600 | $0.8587 |
| Feb 11, 2026 | Bernd R. Seizinger | director | +60,000 | $0.8265 |
Peers
- Theriva Biologics
Oncolytic adenovirus program in metastatic pancreatic cancer
- Agenus
MSS metastatic colorectal immunotherapy program
- Replimune Group
Oncolytic-immunotherapy platform with liver and biliary trials
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Oncolytics Biotech | $0.8526 | −0.79% | $86.0M | — | — | — | — |
| Theriva Biologics | $0.2500 | +2.17% | $11.2M | — | — | 37.5 | — |
| Agenus | $7.66 | 0.00% | $319.0M | 2.9 | — | 2.4 | +34.3% |
| Replimune Group | $15.45 | −0.39% | $1.30B | — | — | — | — |
| Median | 2.9 | — | 19.9 | +34.3% |